Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PASSIGLIA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.047
EU - Europa 1.137
AS - Asia 568
OC - Oceania 5
AF - Africa 4
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.767
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.038
IT - Italia 451
CN - Cina 281
SG - Singapore 197
DE - Germania 148
FI - Finlandia 108
GB - Regno Unito 95
RU - Federazione Russa 84
IE - Irlanda 83
SE - Svezia 38
BE - Belgio 27
IN - India 21
RO - Romania 20
UA - Ucraina 18
TR - Turchia 16
FR - Francia 12
KR - Corea 12
ES - Italia 11
JP - Giappone 10
NL - Olanda 9
CA - Canada 8
CH - Svizzera 8
IR - Iran 8
HK - Hong Kong 6
DK - Danimarca 4
UZ - Uzbekistan 4
AU - Australia 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
PL - Polonia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HR - Croazia 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
NZ - Nuova Zelanda 2
AL - Albania 1
AR - Argentina 1
AT - Austria 1
BR - Brasile 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
ID - Indonesia 1
IL - Israele 1
JM - Giamaica 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.767
Salva come PNG Salva come JPEG
Città #
Fairfield 1.025
Woodbridge 463
Ashburn 457
Seattle 432
Cambridge 353
Wilmington 353
Chandler 351
Houston 345
Ann Arbor 196
Singapore 166
Palermo 110
Medford 84
Dublin 81
Altamura 70
Nanjing 70
Des Moines 59
Princeton 54
Lawrence 51
San Diego 48
Santa Clara 45
Saint Petersburg 36
Dearborn 33
Beijing 31
Ludwigshafen am Rhein 31
New York 30
Boardman 28
Brussels 26
Kitzingen 26
London 21
Shenyang 20
Jinan 18
Phoenix 18
Hebei 17
Redwood City 17
Tianjin 17
Bremen 13
Changsha 13
Izmir 13
Nanchang 13
Tulsa 13
Jiaxing 12
Helsinki 11
Kumar 11
Chicago 9
Ningbo 9
Rome 9
San Paolo di Civitate 9
Seongnam 9
Milan 8
Zhengzhou 8
Los Angeles 7
Pune 7
Amsterdam 6
Falls Church 6
Edinburgh 5
Hong Kong 5
Kilburn 5
Nürnberg 5
Orange 5
Tehran 5
Cagliari 4
Hangzhou 4
Hanover 4
Jacksonville 4
Madrid 4
Moscow 4
Napoli 4
Norwalk 4
San Mateo 4
Tappahannock 4
Tokyo 4
Walnut 4
Abidjan 3
Chiswick 3
Columbus 3
Detroit 3
Fuzhou 3
Kunming 3
Montepulciano 3
Shanghai 3
Zurich 3
Aci Sant'antonio 2
Barcelona 2
Dallas 2
Frankfurt am Main 2
Fremont 2
Guangzhou 2
Huzhou 2
Islington 2
Lanzhou 2
Las Vegas 2
Lublin 2
Lucca 2
Macau 2
Mehlingen 2
Mississauga 2
Munich 2
Padova 2
Pisa 2
Raffadali 2
Totale 5.511
Salva come PNG Salva come JPEG
Nome #
EGFR inhibition in NSCLC: New findings…. and opened questions? 253
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 216
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 201
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 192
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 190
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 188
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 172
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 169
Nintedanib in NSCLC: Evidence to date and place in therapy 163
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 159
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression 157
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 153
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 152
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 152
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 152
Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. 151
The role of targeted therapy for gastrointestinal tumors 150
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 145
Multisciplinary management of patients with liver metastasis from colorectal cancer 144
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 143
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 141
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 141
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 139
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 139
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 135
Cancer and the microbiome: Potential applications as new tumor biomarker 135
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 134
Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC) 133
Liquid biopsies in lung cancer: The new ambrosia of researchers 131
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 129
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer 129
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) 129
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway 129
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 124
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib? 122
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 118
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 117
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 112
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 110
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 110
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 108
Ramucirumab and its use in gastric cancer treatment 106
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 102
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 97
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 78
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 76
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab 73
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 73
null 69
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 68
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 64
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 62
Immune-Biomarkers in Advanced Non-Small Cell Lung Cancer 60
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 54
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 43
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 26
Totale 7.118
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.812
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.812
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.397 0 0 0 0 244 263 215 178 199 120 136 42
2020/2021989 93 34 114 66 55 55 64 81 96 141 104 86
2021/2022737 35 138 58 24 34 36 31 63 65 82 58 113
2022/20231.011 101 211 30 126 103 146 49 76 88 10 48 23
2023/2024396 14 59 33 28 19 67 55 25 5 11 7 73
2024/2025357 18 120 107 83 29 0 0 0 0 0 0 0
Totale 7.118